trial

Schizophrenic Patients in Integrated Care

NCTId NCT00681629
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Terminated
Enrollment 7 (actual)
Sponsored by AstraZeneca
Primary completion 2008-11
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Terminated
Enrollment
7 (actual)
Study type
Interventional
Allocation
Non Randomized
Model
Parallel
Masking
None
Start
2008-07
Primary completion
2008-11
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
QuetiapineIntegrated Care Program (ICP)

Sponsors

AstraZenecaLead Sponsor

Investigators

1
Martin Lambert, ProfessorPrincipal Investigator

Sites

8 total
München, GermanyOranienburg, GermanyHamburg, GermanyLüneburg, GermanyOldenburg, GermanyChemnitz, GermanyBerlin, GermanyStolberg, Germany

Facts & assertions

4 sourced
Enrollment
7
Phase
PHASE4
Primary Completion Date
2008-11
Status
TERMINATED
relationships
The graph out of here
drug
Quetiapine
drug
Integrated Care Program (ICP)
drug
lead_sponsor
AstraZeneca
company
indication
Schizophreniform Disorder
indication
Schizoaffective Disorder
indication
Psychotic Disorders
indication
investigator
Martin Lambert, Professor
person